Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHDGlobeNewsWire • 11/21/23
Key Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL ApprovalGlobeNewsWire • 09/21/23
Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023GlobeNewsWire • 08/30/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mesoblast Limited - MESOPRNewsWire • 08/29/23
Mesoblast Receives Complete Response From U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in ChildrenGlobeNewsWire • 08/04/23
Are You Looking for a Top Momentum Pick? Why Mesoblast Limited (MESO) is a Great ChoiceZacks Investment Research • 06/23/23
Mesoblast Reports Operational and Financial Highlights for Quarter Ended March 31, 2023GlobeNewsWire • 05/25/23
FDA Accepts Mesoblast's Resubmission of the Biologic License Application for Remestemcel-L In Children with Steroid-Refractory Acute Graft Versus Host Disease as a Complete Response and Sets Goal Date of August 2, 2023GlobeNewsWire • 03/08/23
Mesoblast Reports Operational and Financial Highlights for Quarter Ended December 31, 2022GlobeNewsWire • 02/27/23